Company Overview
ABVC BioPharma, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to developing drugs and medical devices designed to address unmet medical needs within the United States. The company functions within the broader healthcare sector, specifically categorized under the biotechnology industry, which implies a focus on early-stage innovation and clinical development rather than established commercial product lines. This biotechnology firm maintains a market capitalization of $25.44M and employs 16 individuals to execute its research and development initiatives. The combination of a market cap under $30 million and an absence of reported annual revenue indicates that the company is in a pre-revenue or early commercialization phase, positioning it as a high-risk, high-potential entity focused entirely on advancing its pipeline assets like ABV-1501 and ABV-1504 before generating significant sales figures.
Financial Health
The company reports Net Income (TTM) of $-7,908,554 and EBITDA of $-7,125,929, while Revenue (TTM) is not available, suggesting that current losses are primarily driven by operational expenses associated with clinical trials and development rather than sales costs. The substantial gap between the reported net income loss and the EBITDA loss highlights the intensity of non-operating expenses or specific accounting adjustments impacting the bottom line relative to core operational earnings. Despite the negative net income, the company generated Free Cash Flow of $721,904, which indicates a degree of financial flexibility allowing for continued operations and potential cash reserves to fund R&D activities without immediate external capital infusion. The Gross Margin stands at 0.0%, the Operating Margin at 375.8%, and the Profit Margin at 0.0%; the zero gross and profit margins reflect the lack of revenue to calculate margins on, while the anomalous operating margin suggests a specific accounting environment where operating expenses may be lower than operating revenue in a non-traditional manner or reflect pre-revenue accounting treatments. On the balance sheet, Cash stands at $745,834 while Debt totals $3.47M, resulting in a Debt to Equity ratio of 26.12, which indicates a leveraged position where debt obligations significantly exceed equity capitalization. The Current Ratio is 0.41, signaling that current liabilities exceed current assets and implying potential short-term liquidity challenges as the company manages its limited cash against upcoming obligations. Return on Equity is -119.5% and Return on Assets is -31.3%, metrics that reveal management is currently destroying shareholder value and utilizing assets to generate losses typical of a pre-revenue biotech firm in deep clinical development.
Valuation Assessment
The Trailing P/E Ratio (TTM) is N/A due to negative earnings, while the Forward P/E is -2.27, a metric that implies the market is pricing in future earnings recovery but is currently distorted by the company's significant accumulated losses. The Price to Book ratio is 2.19, indicating that the market values the company at more than double its net book value, which suggests a premium assigned to the potential of its clinical pipeline assets despite the lack of commercial revenue. The Price to Sales ratio is N/A and the EV/EBITDA is -4.16, which suggests that traditional valuation multiples are not applicable in a standard manner due to the absence of sales and negative earnings, requiring reliance on alternative metrics like cash burn or milestone potential. The 52-Week High is $5.48 and the 52-Week Low is $0.69, meaning the stock has experienced extreme volatility over the past year with a trading range spanning nearly eight times in value. The Beta is 0.27, which indicates that the stock's price volatility is significantly lower than the broader market, a characteristic often seen in small-cap biotech stocks that may be driven more by specific clinical trial outcomes than general market sentiment.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both N/A, reflecting the company's status as a pre-revenue entity where historical growth rates cannot be calculated against prior periods of sales generation. Since the company does not pay dividends, the Dividend Yield is N/A and the Payout Ratio is 0.0%, which means the company reinvests all available resources and cash flow directly into research, development, and clinical trial expansion rather than distributing income to shareholders. The absence of a dividend yield combined with negative earnings growth confirms that the firm is in an accumulation phase where capital is retained to advance its drug candidates and medical devices to market. Overall, the growth and income profile is characterized by zero current income distribution and undefined growth rates, relying entirely on the successful progression of its clinical-stage assets to unlock future commercial value.